GNOSIS: Guidelines for neuro-oncology: Standards for investigational studies—reporting of phase 1 and phase 2 clinical trials
Authors:
- Susan M. ChangSCSusan M. Chang
- Sharon L. ReynoldsSRSharon L. Reynolds
- Nicholas ButowskiNBNicholas Butowski
- Kathleen R. LambornKLKathleen R. Lamborn
- Jan C. BucknerJBJan C. Buckner
- Richard S. KaplanRKRichard S. Kaplan
- Darell D. BignerDBDarell D. Bigner
Open Access
- 1 October 2005
- journal article
- guideline
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 7 (4) , 425-434
Abstract
We present guidelines to standardize the reporting of phase 1 and phase 2 neuro-oncology trials. The guidelines are also intended to assist with accuKeywords
This publication has 22 references indexed in Scilit:
- Randomized Phase II Designs in Cancer Clinical Trials: Current Status and Future DirectionsJournal of Clinical Oncology, 2005
- Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysisNeuro-Oncology, 2004
- Improving the Reporting Quality of Nonrandomized Evaluations of Behavioral and Public Health Interventions: The TREND StatementAmerican Journal of Public Health, 2004
- Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium studyNeuro-Oncology, 2004
- Moving targets and ghosts of the past: outcome measurement in brain tumour therapyJournal of Clinical Neuroscience, 2002
- Response and progression in recurrent malignant gliomaNeuro-Oncology, 1999
- Primary and secondary glioblastomas: From concept to clinical diagnosisNeuro-Oncology, 1999
- More Informative Abstracts RevisitedAnnals of Internal Medicine, 1990
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Steroid‐induced CT changes in patients with recurrent malignant gliomaNeurology, 1988